Dijkstra C D, van der Voort E R, De Groot C J, Huitinga I, Uitdehaag B M, Polman C H, Berkenbosch F
Department of Histology, Research Institute of Neurosciences, Amsterdam, The Netherlands.
Psychoneuroendocrinology. 1994;19(2):135-42. doi: 10.1016/0306-4530(94)90003-5.
We examined the effect of bromocriptine (BCR) treatment on the duration and severity of neurological symptoms of acute experimental allergic encephalomyelitis (EAE), an animal model for demyelinating diseases, particularly multiple sclerosis. To mimic the clinical situation, BCR treatment was started after the onset of clinical signs. Furthermore, the effect of BCR treatment on the course of a chronic relapsing form of EAE was studied. BCR was injected at daily intervals in a dose that resulted in sustained suppression of plasma concentrations of prolactin, a pituitary hormone that plays a role in immunoregulation. In acute EAE, BCR therapy reduced both severity and duration of the clinical signs. In chronic relapsing EAE, BCR treatment did not affect the severity and duration of the first attack, but reduced the duration of the subsequent, second attack. Thus, BCR treatment improves the clinical course in animals with ongoing disease. These findings may have implications for the search for new therapeutic approaches in multiple sclerosis.
我们研究了溴隐亭（BCR）治疗对急性实验性自身免疫性脑脊髓炎（EAE）神经症状持续时间和严重程度的影响，EAE是一种脱髓鞘疾病（尤其是多发性硬化症）的动物模型。为模拟临床情况，在出现临床症状后开始BCR治疗。此外，还研究了BCR治疗对慢性复发性EAE病程的影响。每天间隔注射BCR，剂量能持续抑制催乳素的血浆浓度，催乳素是一种在免疫调节中起作用的垂体激素。在急性EAE中，BCR治疗降低了临床症状的严重程度和持续时间。在慢性复发性EAE中，BCR治疗不影响首次发作的严重程度和持续时间，但缩短了随后第二次发作的持续时间。因此，BCR治疗改善了患病动物的临床病程。这些发现可能对寻找多发性硬化症的新治疗方法具有启示意义。
